Navigation Links
Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
Date:1/3/2008

ation clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 His Majesty Willem-Alexander, ... , The Court of His Majesty Willem-Alexander, King of ... the Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY ... 3. , The King will take part in the ... scheduled for 11 a.m.-12:20 p.m. and tour the plant. ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
(Date:8/21/2014)...  China Cord Blood Corporation (NYSE: CO ... financial results for the first quarter of fiscal year ... in the US.  The Company will ... Friday, August 29, 2014 to discuss its financial performance ... developments, followed by a question and answer session.  Interested ...
(Date:8/21/2014)... Ontotext S4 , The Self Service ... Now the same enterprise hardened text mining, Linked ... data is available to start-ups and mid-size businesses at ... that do not have resources to evaluate and prototype ... since there is no need for on premise hardware ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... more than $80 million to create a leading center ... ... Oct. 16 Fueled by a grant from the John S.,and ... the creation of the BioInnovation Institute in,Akron -- a unique collaboration ...
... ST. LOUIS, Oct. 16 ISTO Technologies, Inc., ... data,related to its NuQu(TM) injectable cell-based therapy for ... Canada at the 23rd Annual,Meeting of the North ... of California San Francisco (UCSF) Department of Orthopedics,were ...
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical ... 2008 financial results will be released on,Thursday, October 30, ... webcast at 10:00 a.m. Eastern Time, October 30, 2008, ... session hosted by Steven G.,Anderson, president and CEO of ...
Cached Biology Technology:BioInnovation Institute in Akron Launched 2BioInnovation Institute in Akron Launched 3BioInnovation Institute in Akron Launched 4Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society 2CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results 2
(Date:8/20/2014)... -- Bay Area Lyme Foundation, which aims to make ... applauds new research published in an upcoming issue of ... Diseases . The findings show that ticks that ... the year, making the threat of Lyme disease year-round. ... of Public Health (CDPH) Vector-borne Disease Section and University ...
(Date:8/20/2014)... salty aroma of sunscreen and seawater signals a relaxing ... that the idyllic beach vacation comes with an environmental ... into the sea, they can become toxic to some ... course for many other marine animals. Their study appears ... . , Antonio Tovar-Sanchez and David Snchez-Quiles point out ...
(Date:8/20/2014)... are poor experience higher cortisol levels in pregnancy and ... stress hormone, putting them at greater risk for ... research from the University of Colorado Denver. , The ... of Human Biology , is the first to measure ... socioeconomic status of their mothers during pregnancy. , "There ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3CU Denver researcher shows economic disparities impact infant health 2
... the Institute for Stem Cell Biology and Medicine have demonstrated ... be genetically manipulated and coaxed to develop into mature T-cells, ... The study, to be published the week of July 3 ... Academy of Sciences, found that it is possible to convert ...
... skyrocketed from 497 cases reported in 1982 (the first year ... , Lyme disease, like other zoonoses, is ... a blood meal from a vertebrate host. In the eastern ... blacklegged ticks, Ixodes scapularis, which feed on a wide variety ...
... University of North Carolina at Chapel Hill has identified ... potentially dangerous interactions with certain medications. , For almost ... and pharmacists to avoid grapefruit juice if they are ... control blood pressure or lower cholesterol. Studies have shown ...
Cached Biology News:UCLA researchers develop T-cells from human embryonic stem cells 2A new view on Lyme disease: Rodents hold the key to annual risk 2A new view on Lyme disease: Rodents hold the key to annual risk 3Study identifies substances in grapefruit juice that interact dangerously with some drugs 2
... Accurate Results Laser Capture Microdissection (LCM) ... and accuracy of molecular assays by starting ... multi-cellular structures isolated from whole tissue or ... in 1996 at the National Institutes of ...
... Conjugated peptides, recombinant or native proteins are ... an immunization protocol optimized in time, quantity of ... recommend the use of 2 animals per protocol ... serum yield on a 77-day protocol is approximately ...
... raised against a partial recombinant ... ZFHX4 (NP_078997, 2 a.a. ... protein with GST tag. ... NM_024721 Protein ...
...
Biology Products: